Long-term evolution and predictive factors of mild inflammatory bowel disease

被引:11
|
作者
Reenaers, C. [1 ]
Pirard, C. [1 ]
Vankemseke, C. [1 ]
Latour, P. [1 ]
Belaiche, J. [1 ]
Louis, E. [1 ]
机构
[1] Univ Hosp Liege, Dept Gastroenterol, Liege, Belgium
关键词
Benign evolution; mild IBD; complication; predictive factor; CROHNS-DISEASE; ULCERATIVE-COLITIS; COLORECTAL-CANCER; CLINICAL-COURSE; RISK; CLASSIFICATION; INFECTIONS; MORTALITY; COLECTOMY; BEHAVIOR;
D O I
10.3109/00365521.2015.1128965
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Crohn's disease (CD) and ulcerative colitis (UC) are potentially progressive diseases. Few data are available on the prevalence and the factors associated with mild inflammatory bowel diseases (IBD). Aim Our aim was to assess the natural history of mild CD and mild UC and to identify predictive factors of mild evolution over the long term. Methods Retrospective study of IBD patients registered in the database of the university hospital CHU of Liege, Belgium. Mild CD was defined as an inflammatory luminal disease (no stricture, abdominal or perianal fistulae) requiring no immunomodulator (IM), anti-TNF and no surgery. Mild UC was defined as no requirement for IM, anti-TNF and no colectomy. Results Four hundred and seventy-three CD and 189 UC were included (median follow-up: 13 and 11 years respectively). At 1 year, 147 patients had mild CD. At 5 years and the maximum follow-up, 56% and 13% patients still had mild CD, respectively. At 1 year, 142 patients had mild UC. At 5 years and the maximum follow-up, 72% and 44% still had a mild UC, respectively. Factors associated with long-term mild CD and UC were older age at diagnosis and absence of corticosteroids in the first year. In UC proctitis location was associated with mild UC. Conclusions In this cohort, 90% of CD patients and 3/4 of UC with mild disease at 1 year lost their mild disease status over time. An old age at diagnosis was predictive of the persistence of a mild CD and UC.
引用
收藏
页码:712 / 719
页数:8
相关论文
共 50 条
  • [1] FACTORS IN THE LONG-TERM PROGNOSIS OF PATIENTS WITH INFLAMMATORY BOWEL-DISEASE
    FARMER, RG
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1981, 75 (02): : 97 - 103
  • [2] The Long-Term Predictive Properties of the Paris Classification in Paediatric Inflammatory Bowel Disease Patients
    Assa, Amit
    Rinawi, Firas
    Shamir, Raanan
    JOURNAL OF CROHNS & COLITIS, 2018, 12 (01): : 39 - 47
  • [3] Inflammatory bowel disease: long-term therapeutic challenges
    Ashton, James J.
    Green, Zachary
    Kolimarala, Vinod
    Beattie, R. Mark
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (11) : 1049 - 1063
  • [4] Long-term safety of vedolizumab for inflammatory bowel disease
    Loftus, Edward V., Jr.
    Feagan, Brian G.
    Panaccione, Remo
    Colombel, Jean-Frederic
    Sandborn, William J.
    Sands, Bruce E.
    Danese, Silvio
    D'Haens, Geert
    Rubin, David T.
    Shafran, Ira
    Parfionovas, Andrejus
    Rogers, Raquel
    Lirio, Richard A.
    Vermeire, Severine
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (08) : 1353 - 1365
  • [5] Long-term outcomes of pediatric inflammatory bowel disease
    Nasiri, Soheila
    Kuenzig, Mary Ellen
    Benchimol, Eric I.
    SEMINARS IN PEDIATRIC SURGERY, 2017, 26 (06) : 398 - 404
  • [6] LONG-TERM PROGNOSIS OF INFLAMMATORY BOWEL-DISEASE
    FARMER, RG
    POSTGRADUATE MEDICINE, 1981, 70 (04) : 124 - &
  • [7] Factors predictive of long-term failure of artificial bowel sphincter
    Wexner, S.
    Li, V.
    Pulido, N.
    Person, B.
    Wang, H.
    Sands, D.
    Weiss, E.
    Nogueras, J.
    Jin, H. Ying
    DISEASES OF THE COLON & RECTUM, 2008, 51 (05) : 797 - 797
  • [8] LONG-TERM SCHEDULED THERAPY WITH INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE
    Armuzzi, A.
    Marzo, M.
    Felice, C.
    Mocci, G.
    De Vincentis, F.
    Andrisani, G.
    Pugliese, D.
    Fedeli, P.
    De Vitis, I.
    Papa, A.
    Gasbarrini, A.
    Guidi, L.
    DIGESTIVE AND LIVER DISEASE, 2010, 42 : S88 - S88
  • [9] LONG-TERM SCHEDULED THERAPY WITH INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE
    Armuzzi, A.
    De Vincentis, F.
    Marzo, M.
    De Pascalis, B.
    Roberto, I.
    Mocci, G.
    Fiore, F.
    Leso, V.
    Fedeli, P.
    Papa, A.
    De Vitis, I.
    Melina, D.
    Fedeli, G.
    Gasbarrini, A.
    Guidi, L.
    DIGESTIVE AND LIVER DISEASE, 2008, 40 : S12 - S12
  • [10] Long-term scheduled therapy with infliximab in inflammatory bowel disease
    Armuzzi, Alessandro
    De pascalis, Barbara
    Roberto, Italia
    Ennas, Sara
    De vincentis, Fabio
    Guglielmo, Simona
    Fedeli, Paolo
    Papa, Alfredo
    De vitis, Italo
    Gasbarrini, Giovanni
    Melina, Domenico
    Fedeli, Giuseppe
    Gasbarrini, Antonio
    Guidi, Luisa
    GASTROENTEROLOGY, 2007, 132 (04) : A183 - A183